This website uses cookies to improve user experience. By continuing to use this website, you consent to our use of cookies and the other terms of our Privacy Policy. For more information, please visit our Privacy Policy.

REVCOVI® ORDERING INFORMATION

For information about ordering, please contact Chiesi Total Care℠.
PHONE: 866-272-7078.

Healthcare providers, please click here to access the Physician Order/Prescription Form. Fax completed forms to 866-272-7079.

For an important update regarding Revcovi's NDC please click here.

ONE-STOP PATIENT SUPPORT

Chiesi Total Care is a comprehensive support program that provides exceptional service for your patients. A single call to your dedicated Chiesi Total Care Team is all it takes to begin the process of getting your patient started on Revcovi. Chiesi Total Care has the ability to provide assistance to patients with or without commercial insurance, Medicaid, or Medicare. The program also offers injection support for patients who receive Revcovi injections at home.

CHIESI TOTAL CARE CO-PAY PROGRAM

Patients may pay as little as $0 for their prescription.*

Program Eligibility:

  • Patient must be enrolled in Chiesi Total Care (enrollment form can be found here)
  • Patient has commercial insurance and a valid prescription for a US Food and Drug Administration (FDA)–approved indication for Revcovi
  • Patient must be a resident of the United States or one of its territories

*Please refer to the full Terms and Conditions on for additional eligibility requirements

MEDICAL INFORMATION AND ADVERSE EVENT REPORTING

For adverse event reporting, product complaints, or medical information inquiries:

PHONE: 1-888-661-9260
FAX: 1-866-443-3092
EMAIL: us.medical@chiesi.com

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/Safety/MedWatch/ or call 1-800-FDA-1088.

PRIVACY POLICY

Where applicable, personal information shared and processed for adverse events reporting, product orders, reimbursement support, and patient assistance is subject to Chiesi's Privacy Policy available at https://www.chiesiusa.com/privacy-policy/.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

  • Injection site bleeding in patients with thrombocytopenia: Increased risk of local bleeding in patients with thrombocytopenia; should not be used if thrombocytopenia is severe.
  • Delay in improvement of immune function: Protect immune deficient patients from infections until improvement in immune function.

ADVERSE REACTIONS

The most commonly reported adverse reactions were cough (50%) and vomiting (33%).

In addition, the following post-marketing reports for the same class of enzyme replacement therapy used in the treatment of ADA-SCID may also be seen with Revcovi treatment:

  • Hematologic events: hemolytic anemia, autoimmune hemolytic anemia, thrombocythemia, thrombocytopenia and autoimmune thrombocytopenia
  • Dermatological events: injection site erythema, urticaria
  • Lymphomas

IMPORTANT MONITORING INFORMATION

Treatment with Revcovi should be monitored by measuring trough plasma ADA activity and trough dAXP levels for maintenance of therapeutic targets. If a persistent decline in plasma ADA activity occurs, immune function and clinical status should be monitored closely, and precautions should be taken to minimize the risk of infection.

INDICATION

Revcovi® (elapegademase-lvlr) is indicated for the treatment of adenosine deaminase severe combined immune deficiency (ADA-SCID) in pediatric and adult patients.

Please see the Full Prescribing Information.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

  • Injection site bleeding in patients with thrombocytopenia: Increased risk of local bleeding in patients with thrombocytopenia; should not be used if thrombocytopenia is severe.
  • Delay in improvement of immune function: Protect immune deficient patients from infections until improvement in immune function.

ADVERSE REACTIONS

The most commonly reported adverse reactions were cough (50%) and vomiting (33%).

In addition, the following post-marketing reports for the same class of enzyme replacement therapy used in the treatment of ADA-SCID may also be seen with Revcovi treatment:

  • Hematologic events: hemolytic anemia, autoimmune hemolytic anemia, thrombocythemia, thrombocytopenia and autoimmune thrombocytopenia
  • Dermatological events: injection site erythema, urticaria
  • Lymphomas

IMPORTANT MONITORING INFORMATION

Treatment with Revcovi should be monitored by measuring trough plasma ADA activity and trough dAXP levels for maintenance of therapeutic targets. If a persistent decline in plasma ADA activity occurs, immune function and clinical status should be monitored closely, and precautions should be taken to minimize the risk of infection.

INDICATION

Revcovi® (elapegademase-lvlr) is indicated for the treatment of adenosine deaminase severe combined immune deficiency (ADA-SCID) in pediatric and adult patients.

Please see the Full Prescribing Information.

You are now leaving the Revcovi HCP website.

This external link is provided for your convenience. Chiesi is not responsible for content on external websites.

Ok, ContinueReturn to Site